Radiotherapy in Good-Prognosis DLBCL

Get Permission

Thierry Lamy, MD, PhD

Radiotherapy After R-CHOP in DLBCL

With the current follow-up, the addition of radiotherapy is not significantly superior to R-CHOP alone and should be reserved for the minority of patients who do not reach complete response after R-CHOP.

—Thierry Lamy, MD, PhD

Limited-stage nonbulky diffuse large B-cell lymphoma (DLBCL) carries an excellent prognosis, and radiotherapy provides no value in patients who obtain a complete response, according to the phase III 02-03 trial from the Lysa/Goelams group, presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.1

“The benefit of radiotherapy following chemotherapy in limited-stage DLBCL remains controversial. Before the ‘rituximab [Rituxan] era,’ four randomized trials turned in conflicting results. More recently, the German Unfolder study prematurely closed the R-CHOP without radiotherapy arm in bulky limited-stage DLBCL due to an excess of relapse,” said Thierry Lamy, MD, PhD, of the University Hospital of Rennes in France.

To further examine the benefit of radiotherapy after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in this population, Dr. Lamy and colleagues initiated a randomized trial in patients with nonbulky (tumor size < 7 cm) limited-stage DLBCL in 2005.

They concluded that radiotherapy following R-CHOP is of no value to the vast majority of patients.

“With the current follow-up, the addition of radiotherapy is not significantly superior to R-CHOP alone and should be reserved for the minority of patients who do not reach complete response after R-CHOP,” Dr. Lamy said.

Study Details

Depending on risk factors, patients received 4 or 6 consecutive cycles of R-CHOP14, followed or not by involved-field radiotherapy at 40 Gy delivered 4 weeks after the last cycle of R-CHOP. All patients were evaluated by fluorodeoxyglucose–positron emission tomography (FDG-PET) at baseline, after 4 cycles of R-CHOP, and at the end of treatment. 

The recommendation was that patients in partial response (tumor regression > 50% but a persistent positive FDG-PET) after cycle 4 receive an additional 2 cycles of R-CHOP followed by radiotherapy. The primary objective was event-free survival 1 year after the last randomization.

There were 301 evaluable patients (median age, 56 years), of whom 82% had normal LDH levels, 96% had no B symptoms, and the majority had an International Prognostic Index score of 1 to 2. The main tumor site was cervical lymph nodes, and 40% had extranodal sites.

No Additional Benefit of Radiotherapy

No significant benefit was observed in the cohort receiving radiotherapy after R-CHOP (n = 151) compared with the group receiving R-CHOP alone (n = 150). Complete response rates overall were 84%, and 14% of patients attained partial responses and three patients had stable disease.

In the intent-to-treat analysis, after 51 months’ median follow-up, event-free survival at 5 years was 88%, with 88.4% for the radiotherapy arm and 87.3% for the R-CHOP alone arm (P = .13). Overall survival was 91% for the whole population and 92% for the radiotherapy arm and 90% for the R-CHOP–alone arm (P = .33), Dr. Lamy reported.

By assignment group, complete responses were observed in 82% after R-CHOP alone and 85% after R-CHOP plus radiotherapy; partial responses (PET-positive) were observed in 16% and 12%, and stable disease was noted in one and two patients, respectively.

At the end of treatment, complete responses were observed in 93% and 95%, respectively. There were partial responses in seven patients treated with R-CHOP alone and one patient treated with R-CHOP plus radiotherapy, and stable disease was reported in two patients in the R-CHOP arm, Dr. Lamy added.

For the 43 patients who were partial responders after cycle 4, 37 (86%) received 2 additional cycles of R-CHOP plus radiotherapy, whereas 6 patients were treated with a different regimen, with or without radiotherapy. Of these 43 patients, 40 ultimately attained a complete response. After complete response, 5-year event-free survival was 89% in the R-CHOP–alone arm, and 91% in the R-CHOP plus radiotherapy arm.

“After 4 cycles of R-CHOP, adding 2 cycles plus radiotherapy for patients in partial response induced similar outcomes as compared to patients who obtained a complete response,” Dr. Lamy pointed out.

Relapses occurred in 12 patients (8%) in the R-CHOP–alone arm and 8 patients (5%) of the arm receiving R-CHOP plus radiotherapy, which was not a significant difference. The median time to relapse was 21 months. In the radiotherapy arm, none of these relapses occurred at the initial tumor site, but in the R-CHOP–alone arm, 5 of 12 relapses occurred at that site. Altogether, nine patients developed progressive disease.

“In this prospective study, the results demonstrate that in nonbulky limited-stage DLBCL, R-CHOP alone for 4 to 6 cycles induces very high complete response rates, with a very good overall survival and a very low relapse rate,” he concluded. ■

Disclosure: Dr. Lamy reported no potential conflicts of interest.


1. Lamy T, Damaj G, Gyan E, et al: R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): Preliminary results of the prospective randomized phase III 02-03 trial from the Lysa/Goelams Group. 2014 ASH Annual Meeting. Abstract 393. Presented December 8, 2014.





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.